Related Experiment Video
Updated: May 8, 2026
07:47
Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker
Published on: September 15, 2023
PTK7 expression in triple-negative breast cancer
Beyhan Ataseven1, Regina Angerer, Ronald Kates
1Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Henricistrasse 92, 45136 Essen, Germany. ataseven@gmx.net.
Anticancer Research
|September 12, 2013
Summary
Protein tyrosine kinase-7 (PTK7) may indicate resistance to anthracycline chemotherapy in triple-negative breast cancer (TNBC). PTK7-negative tumors showed better survival outcomes, especially with anthracycline-based treatments.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Protein tyrosine kinase-7 (PTK7) is implicated in various cancers.
- Triple-negative breast cancer (TNBC) is an aggressive subtype with limited targeted therapies.
Purpose of the Study:
- To investigate the role and prognostic significance of PTK7 in TNBC.
- To correlate PTK7 expression with clinicopathological features and patient survival.
Main Methods:
- Immunohistochemistry (IHC) was used to assess PTK7 expression in 133 TNBC patient tumor samples.
- Expression levels were analyzed in relation to clinical data and survival outcomes, considering chemotherapy treatment.
Main Results:
- PTK7 expression was observed in 28.6% of TNBC tumors.
- No overall significant association between PTK7 status and disease-free survival (DFS) or overall survival (OS) was found.
- However, PTK7-negative tumors were linked to improved DFS in patients receiving chemotherapy, particularly those treated with anthracyclines.
Conclusions:
- PTK7 expression may be associated with resistance to anthracycline-based chemotherapy in TNBC.
- These findings suggest PTK7 as a potential predictive biomarker for treatment response.
